All In Biotech

Drug Trial Radar · NCT00616928

Immunogenicity & Safety of GSK's Influenza Vaccine 1557484A Given to Adults Aged ≥18 Years

A Trial to Evaluate the Safety and Immunogenicity of an Investigational Vaccination Regimen in Adults Aged ≥18 Years

Last checked: Nov 20, 2026Latest source record: Jun 8, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 4,561 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,561

Actual

Start

Jan 23, 2008

Primary completion

Oct 15, 2008

Study completion Mar 19, 2009

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Feb 15, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this Phase 3, observer-blind, placebo-controlled, multi-center study is to characterize the immunogenicity \& safety of the investigation vaccination regimen of GSK 1557484A vaccine given to adults aged ≥18 years.

Conditions

  • Influenza

Interventions

  • Influenza A (H5N1) Virus Monovalent Vaccine, AdjuvantedBiological

    Two intramuscular injections at Days 0 and 21.

  • PlaceboBiological

    Two intramuscular injections at Days 0 and 21.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Seroconverted Subjects Against A/Indonesia/5/2005 (H5N1)Time frame: At Day 42 post Dose 1 (Day 42 post Dose 1 = Day 21 post Dose 2)
  2. Number of Seroprotected Subjects Against A/Indonesia/5/2005 (H5N1)Time frame: At Day 0 and Day 42 post Dose 1 (Day 42 post Dose 1 = Day 21 post Dose 2)
  3. Number of Subjects With Any Solicited Local Symptoms.Time frame: During a 7-day follow-up period (i.e., day of vaccination and 6 subsequent days) after each vaccine administration
  4. Number of Subjects With Any Solicited General Symptoms.Time frame: During a 7-day follow-up period (i.e., day of vaccination and 6 subsequent days) after each vaccine administration
  5. Number of Subjects With Any Unsolicited Adverse Events (AEs).Time frame: During a 21-day follow-up period for each vaccine administration, as well as overall (Day 0 through Day 84)
  6. Number of Subjects With Serious Adverse Events (SAEs)Time frame: From Day 0 through Day 182 and through Day 379.
  7. Number of Subjects With Medically Attended Events (MAEs)Time frame: From Day 0 through Day 182 and through Day 364.

Locations

40 sites in 2 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Huntsville, Alabama

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Anaheim, California

  • GSK Investigational Site

    Jacksonville, Florida

  • GSK Investigational Site

    Melbourne, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Pembroke Pines, Florida

  • GSK Investigational Site

    Stockbridge, Georgia

  • GSK Investigational Site

    Chicago, Illinois

  • GSK Investigational Site

    Peoria, Illinois

  • GSK Investigational Site

    South Bend, Indiana

  • GSK Investigational Site

    Lenexa, Kansas

  • GSK Investigational Site

    Wichita, Kansas

  • GSK Investigational Site

    Metairie, Louisiana

  • GSK Investigational Site

    Rockville, Maryland

  • GSK Investigational Site

    St Louis, Missouri

  • GSK Investigational Site

    Missoula, Montana

  • GSK Investigational Site

    Las Vegas, Nevada

  • GSK Investigational Site

    Edison, New Jersey

  • GSK Investigational Site

    Poughkeepsie, New York

  • GSK Investigational Site

    Rochester, New York

  • GSK Investigational Site

    Raleigh, North Carolina

  • GSK Investigational Site

    Cleveland, Ohio

  • GSK Investigational Site

    Erie, Pennsylvania

  • GSK Investigational Site

    Pittsburgh, Pennsylvania

  • GSK Investigational Site

    Spartanburg, South Carolina

  • GSK Investigational Site

    Nashville, Tennessee

  • GSK Investigational Site

    Austin, Texas

  • GSK Investigational Site

    Fort Worth, Texas

  • GSK Investigational Site

    San Angelo, Texas

  • GSK Investigational Site

    Halifax, Nova Scotia, Canada

  • GSK Investigational Site

    Truro, Nova Scotia, Canada

  • GSK Investigational Site

    Greater Sudbury, Ontario, Canada

  • GSK Investigational Site

    London, Ontario, Canada

  • GSK Investigational Site

    Sarnia, Ontario, Canada

  • GSK Investigational Site

    Woodstock, Ontario, Canada

  • GSK Investigational Site

    Pointe-Claire, Quebec, Canada

  • GSK Investigational Site

    Québec, Quebec, Canada

  • GSK Investigational Site

    Saint Romuald, Quebec, Canada

  • GSK Investigational Site

    Sherbrooke, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.